EUVIMEDObjevte EUVIMED
Übersichtsarbeit

Ovarian fibrosis in polycystic ovary syndrome: Mechanisms, evidences, and clinical implications

Sakshi Nalkande, Mrudula Patil, Kartik Nakhate, Sameer Goyal

Differentiation · 2026-07 · 150 · 100976

DOI: 10.1016/j.diff.2026.100976 ↗

At a glance

Übersichtsarbeit in Differentiation, 2026-07. Written by Sakshi Nalkande and 3 co-authors. Institution: SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, 424001, India. Major MEDLINE topics: Polycystic Ovary Syndrome, Fibrosis, Ovary. Cited 2 times so far (Crossref); 115 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Polycystic ovary syndrome (PCOS) is a complex heterogeneous endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. Emerging studies suggest that ovarian fibrosis, as an underrecognized pathological feature, may contribute to ovarian dysfunction and infertility in PCOS phenotypes. Available experimental and limited human studies indicate that hyperandrogenism, insulin resistance, chronic low-grade inflammation, oxidative and endoplasmic reticulum stress collectively promote extracellular matrix accumulation and stromal remodeling predominantly through transforming growth factor-β (TGF-β)-mediated signaling pathways. Additionally, fibrotic remodeling has been linked to other pathways, including the NLRP3 inflammasome, PI3K/Akt, Hippo/YAP, and epithelial-mesenchymal transition. Although standardised diagnostic criteria are currently lacking, new imaging modalities, such as shear-wave elastography, and circulating fibrosis-related biomarkers may offer non-invasive approaches to evaluating ovarian fibrotic alterations. Furthermore, several anti-fibrotic agents, metabolic modulators, phytochemicals, and stem cell-based therapies have been suggested to have potential therapeutic effects in ovarian fibrosis models of PCOS. Overall, ovarian fibrosis represents a developing aspect of PCOS pathophysiology that requires further clinical and translational investigation.

Subjects

MeSH terms (MEDLINE)

Polycystic Ovary SyndromeFibrosisOvaryHumansFemaleAnimalsSignal TransductionTransforming Growth Factor betaEpithelial-Mesenchymal TransitionInsulin Resistance

Author keywords

Anti-fibrotic agentsExtracellular matrixFibrotic remodelingOvarian fibrosisPCOSTGF-β

Substances

Transforming Growth Factor beta

Authors and institutions

  • SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, 424001, India.
  • SVKM NMIMS Global University School of Pharmacy and Technology Management, Dhule, Maharashtra, 424001, India. Electronic address: Sameer.Goyal@svkm.ac.in.

Cite

APA

Nalkande, S., Patil, M., Nakhate, K., & Goyal, S. (2026). Ovarian fibrosis in polycystic ovary syndrome: Mechanisms, evidences, and clinical implications. Differentiation, 150, 100976. https://doi.org/10.1016/j.diff.2026.100976

Vancouver

Nalkande S, Patil M, Nakhate K, Goyal S. Ovarian fibrosis in polycystic ovary syndrome: Mechanisms, evidences, and clinical implications. Differentiation. 2026;150:100976. doi:10.1016/j.diff.2026.100976

BibTeX
@article{Nalkande2026,
  author = {Nalkande, Sakshi and Patil, Mrudula and Nakhate, Kartik and Goyal, Sameer},
  title = {Ovarian fibrosis in polycystic ovary syndrome: Mechanisms, evidences, and clinical implications},
  journal = {Differentiation},
  year = {2026},
  volume = {150},
  pages = {100976},
  doi = {10.1016/j.diff.2026.100976}
}
Start for free →